Navigation Links
Possible treatment target found for main cause of severe liver disease in kids
Date:11/8/2011

ne, which points to how immune system dendritic cells trigger the initial immune response in a mouse model of biliary atresia.

The September study reported that dendritic cells which process and transmit signals from the surfaces of tissues to recruit other immune system components activated natural killer cells in the immune system. This activation set off a cascade of hyperactive immune response in the newborn mice, worsening the disease.

Researchers were able to disable the process be depleting or blocking the signaling activity of plasmacytoid dendritic cells and Interleukin 15. This prevented injury of the bile ducts and shut down the disease process. Bezerra cautioned that more research is needed before determining whether blocking this process may have therapeutic benefit in humans.
'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Link possible between pet food contamination and baby formula contamination
2. Inherited genetic cause, possible treatment found for complex lung disorder
3. Argonne scientists discover possible mechanism for creating handedness in biological molecules
4. Vitamin E shows possible promise in easing chronic inflammation
5. Nanotechnology culture war possible, says Yale study
6. Rice University study finds possible clues to epilepsy, autism
7. Pitt, NETL researchers report molecular chain reaction thought to be impossible
8. MU researcher identifies possible genetic causes of borderline personality disorder
9. Our unconscious brain makes the best decisions possible
10. Promising new drug being evaluated as possible treatment option for fragile X syndrome
11. Control of blood vessels a possible weapon against obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... University scientists are working to determine how neurons are ... disorders like Tuberous Sclerosis Complex (TSC). TSC is ... tumors in the brain and other vital organs and ... impairment that may arise from the abnormal generation of ...
... who invest in their own solar panels for the roof ... the long term but how long will this technology ... up to 25 years to their customers, the manufacturers themselves ... modules must fulfill certain standards, of course, to be approved ...
... fundamental processes in the life of plants because they have ... Leeds researchers. Arabidopsis thaliana also known as thale ... over Europe and Asia, but the small white flower leads ... world. It has become the dominant "model plant" in ...
Cached Biology News:Clemson University study points to possible treatment for brain disorders 2Predicting the life expectancy of solar modules 2Predicting the life expectancy of solar modules 3Model plant misled scientists about multicellular growth 2Model plant misled scientists about multicellular growth 3
(Date:4/27/2015)... DIEGO , April 27, 2015  Edico ... biochemists and geneticists from Harvard and Stanford Universities ... a whole genome sequence with 300x depth of ... hours compared to 60 hours with standard software. ... remains a challenge, especially for individual research and ...
(Date:4/27/2015)... LONDON , April 27, 2015 ... about this release, please scroll to bottom . ... following equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX ... Synta Pharmaceuticals Corporation (NASDAQ: SNTA ), Spectrum ... Inc. (NASDAQ: MDVN ). Free research report ...
(Date:4/27/2015)... -- Haemonetics Corporation (NYSE: HAE ) today reported ... $226.5 million, down 6%.  Excluding currency impact, revenue ... reported a fourth quarter GAAP net loss of ... income, exclusive of transformation, restructuring and deal amortization ... and adjusted earnings per share were $0.47, up ...
(Date:4/27/2015)... 2015  MT Services LLC, a Lawsuit Settlement ... that U.S. District Judge Joseph Goodwin ... status meeting in hopes to resolve more than ... manufacturers who are involved in multidistrict litigations under ... going on for some time, and Judge Goodwin ...
Breaking Biology Technology:Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30
... 2012 Alchem International Ltd. opens its ... marketing office will be spearheaded by Laurent Leduc, former ... cater to the rapidly growing demand in North America ... for the supplement, pharmaceutical and cosmetic industries. ...
... NEW YORK, Feb. 1, 2012   Reportlinker.com ... is available in its catalogue: ... and Companies http://www.reportlinker.com/p0203537/Cell-Therapy---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy ... cell therapy technologies and methods, which have ...
... able to hear the imagined speech of a patient unable ... of California, Berkeley, researchers. These scientists have succeeded ... the seat of the auditory system as a person ... and brain activity, they then were able to predict the ...
Cached Biology Technology:Alchem International Opens Sales and Marketing Office in the U.S. 2Cell Therapy - Technologies, Markets and Companies 2Cell Therapy - Technologies, Markets and Companies 3Cell Therapy - Technologies, Markets and Companies 4Cell Therapy - Technologies, Markets and Companies 5Cell Therapy - Technologies, Markets and Companies 6Cell Therapy - Technologies, Markets and Companies 7Cell Therapy - Technologies, Markets and Companies 8Cell Therapy - Technologies, Markets and Companies 9Cell Therapy - Technologies, Markets and Companies 10Cell Therapy - Technologies, Markets and Companies 11Cell Therapy - Technologies, Markets and Companies 12Cell Therapy - Technologies, Markets and Companies 13Cell Therapy - Technologies, Markets and Companies 14Cell Therapy - Technologies, Markets and Companies 15Cell Therapy - Technologies, Markets and Companies 16Scientists decode brain waves to eavesdrop on what we hear 2Scientists decode brain waves to eavesdrop on what we hear 3
Apoptosis Detection Systems and Reagents...
... These plastic feeding tubes for rodent oral ... the risk of perforation and trauma. Plus ... of cleaning and the risk of cross-contamination. ... 20ga Length: ...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
...
Biology Products: